Open Scanner

Specify a stock or a cryptocurrency in the search bar to get a summary

Internet Computer ICP
Bitcoin Cash BCH
Litecoin LTC
Field stub for analysis


Current price
2.11 USD -0.03 USD (-1.40%)
Last closed 2.14 USD
Sector Healthcare
Industry Biotechnology
Exchange NASDAQ
Capitalization 188 359 920 USD
Yield for 12 month +177.63 %
21.11.2021 - 28.11.2021

Compugen Ltd., a clinical-stage therapeutic discovery and development company, researches, develops, and commercializes therapeutic and product candidates in Israel, the United States, and Europe. The company's immuno-oncology pipeline consists of COM701, an anti-PVRIG antibody that is in Phase I clinical study used for the treatment of solid tumors; COM902, a therapeutic antibody targeting TIGIT, which is in Phase I monotherapy clinical study in patients with advanced malignancies through sequential dose escalations; Bapotulimab, a therapeutic antibody targeting ILDR2 that is in Phase I clinical study in patients with naïve head and neck squamous cell carcinoma; and Rilvegostomig, a novel anti-TIGIT/PD-1 bispecific antibody, which is in Phase II clinical study in patients with advanced or metastatic non-small cell lung cancer. Its therapeutic pipeline also includes early-stage immuno-oncology programs focused to address various mechanisms of immune resistance; and COM503, high affinity antibody, which blocks the interaction between IL-18 binding protein and IL-18. The company has collaboration agreement with Bayer Pharma AG for the research, development, and commercialization of antibody-based therapeutics against the company's immune checkpoint regulators; Bristol-Myers Squibb to evaluate the safety and tolerability of COM701 in combination with Bristol-Myers Squibb's PD-1 immune checkpoint inhibitor Opdivo in patients with advanced solid tumors; and Johns Hopkins School of Medicine to evaluate novel T cell and myeloid checkpoint targets. It has license agreement with AstraZeneca for the development of bi-specific and multi-specific immuno-oncology antibody products; and research collaboration with Johns Hopkins University for myeloid. Compugen Ltd. was incorporated in 1993 and is headquartered in Holon, Israel. Address: Azrieli Center, Holon, Israel, 5885849

Check your investment idea

Find the best to beat the market
TSLA TSLA Tesla Motors
MSFT MSFT Microsoft


WallStreet Target Price

5.33 USD

P/E ratio

Dividend Yield

Current Year

+33 459 000 USD

Last Year

+7 500 000 USD

Current Quarter

+33 459 000 USD

Last Quarter

Current Year

+30 979 000 USD

Last Year

+6 525 000 USD

Current Quarter

+31 455 000 USD

Last Quarter

Key Figures CGEN

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
EBITDA -12 516 000 USD
Operating Margin TTM 53.75 %
PE Ratio
Return On Assets TTM -7.54 %
PEG Ratio
Return On Equity TTM -26.19 %
Wall Street Target Price 5.33 USD
Revenue TTM 33 459 000 USD
Book Value 0.74 USD
Revenue Per Share TTM
Dividend Share
Quarterly Revenue Growth YOY 346.1 %
Dividend Yield
Gross Profit TTM 6 525 000 USD
Earnings per share -0.21 USD
Diluted Eps TTM -0.21 USD
Most Recent Quarter IV 2023
Quarterly Earnings Growth YOY
Profit Margin -56.05 %

Dividend Analytics CGEN

Dividend growth over 5 years

Continuous growth

Payout Ratio 5 years average

Dividend History CGEN

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Forward Annual Dividend Rate
Ex Dividend Date
Forward Annual Dividend Yield
Last Split Factor
Payout Ratio
Last Split Date
Dividend Date

Stock Valuation CGEN

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
Forward PE
Enterprise Value Revenue 4.5383
Price Sales TTM 6.044
Enterprise Value EBITDA -12.1322
Price Book MRQ 2.9088

Financials CGEN

1 year
3 years
5 years
10 years
15 years
Results 2019 Dynamics
* The data for this period has not yet been published

Technical indicators CGEN

For 52 weeks

0.53 USD 3.03 USD
50 Day MA 2.34 USD
Shares Short Prior Month 1 948 358
200 Day MA 1.55 USD
Short Ratio 6.44
Shares Short 1 947 742
Short Percent 2.25 %

Dynamics of changes in the value of assets




420.21 USD Microsoft Corporation -1.96 (-0.46%)
Detailed analytics

ETF funds



14.76 EUR iShares EURO STOXX Banks 30-15 UCITS ETF (DE) +0.03 (+0.2%)
Detailed analytics



2414.65 USD Gold +37.17 (+1.56%)
Detailed analytics